Lenz Therapeutics reported positive topline data from the phase 2 INSIGHT clinical trial investigating LNZ100 and LNZ101 for the treatment of presbyopia.
LNZ100 (aceclidine) and LNZ101 (aceclidine plus brimonidine) both met the trial’s primary endpoint of near visual acuity improvement of three lines or greater without losing one line or more in distance visual acuity at 1 hour. Seventy-one percent of patients treated with LNZ100 and 56% of patients treated with LNZ101 met this endpoint compared with 6% of patients treated with vehicle, according to a press release.
Additionally, 37% of